Trump Administration to End Medicare Premium Subsidy Programme

The administration of U.S. President Donald Trump has announced that it will end a federal subsidy programme that has helped keep Medicare Part D prescription drug plan premiums low, a move that could increase monthly costs for millions of American seniors beginning in 2027. The programme, introduced to stabilise the Medicare prescription drug market, will expire at the end of 2026 and will not be renewed.

The subsidy programme was created to cushion insurers from rising prescription drug costs following changes introduced under the Inflation Reduction Act. It has provided an estimated US$3.6 billion in support this year, helping insurers limit premium increases for beneficiaries enrolled in standalone Medicare Part D drug plans. Approximately 25 million Americans currently receive prescription drug coverage through these plans.

Officials at the Centers for Medicare & Medicaid Services (CMS) said the temporary programme has achieved its objective of stabilising the market and argued that insurers now have enough experience to price their plans without additional government support. CMS Administrator Dr. Mehmet Oz said most beneficiaries are expected to see premium increases of less than US$10 per month, while some may experience little or no increase depending on the plan they choose.

However, independent analysts and healthcare experts warn that the end of the subsidy could result in noticeably higher costs for many seniors. According to administration estimates, about 45% of Part D enrollees may see monthly premium increases of between US$11 and US$20 when the new rates take effect in 2027, while others may be able to reduce costs by switching to different plans during the annual enrolment period.

The decision has drawn criticism from consumer advocates, who argue that many older Americans are already struggling with the rising cost of healthcare and prescription medicines. They fear higher premiums could encourage more beneficiaries to move into Medicare Advantage plans, which often include prescription drug coverage but may have narrower provider networks and different coverage rules.

The administration maintains that broader protections introduced under the Inflation Reduction Act remain in place, including the annual cap on out-of-pocket prescription drug costs. Officials argue these reforms will continue to protect beneficiaries even after the premium stabilisation programme ends. Final premium rates for 2027 are expected to be released later this year, giving beneficiaries an opportunity to compare plans before enrolling.

The announcement comes as healthcare spending remains a major political issue in the United States. While the administration says ending the subsidy reflects a return to a more competitive insurance market, opponents argue it risks shifting more of the financial burden onto older Americans living on fixed incomes. The impact of the policy will become clearer once insurers publish their 2027 premiums during the autumn enrolment season.